NCT01643746WithdrawnNot Applicable
C-arm CT Evaluation of Luminal Expansion in Stenting Severe Femoro-popliteal Atherosclerotic Disease: Supera Versus LifeStent
Centre hospitalier de l'Université de Montréal (CHUM)4 sites in 1 countryStarted: December 1, 2017Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Withdrawn
- Sponsor
- Locations
- 4
- Primary Endpoint
- Stent expansion
Study Overview
Brief Summary
The primary goal of this trial is to compare prospectively stent opening of Supera (IDEV Technologies) versus a reference stent (LifeStent, Bard Medical) using C-arm CT. A secondary goal is to correlate stent opening with stent patency as documented by Doppler ultrasound at one year post implantation.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Single (Participant)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age ≥ 18 years
- •Patient (or legally authorized representative) must give a written informed consent.
- •Symptomatic peripheral-artery disease with moderate or severe intermittent claudication and failure of medical treatment (Rutherford stage 2,3) or chronic critical limb ischemia with pain while the patient is at rest (Rutherford stage 4) or chronic critical limb ischemia with ischemic ulcers (Rutherford stage 5, 6) and stenosis of more than 70 percent or occlusion of the ipsilateral superficial femoral artery and/or proximal popliteal artery with a target-lesion length of ≥ 8 and ≤ 20 cm and at least one patent (less than 50 percent stenosed) tibioperoneal runoff vessel (TASC A,B,C lesions)
- •Proximal popliteal artery is defined as the popliteal artery above the joint line. The distal portion of the lesion should be located at least 4 cm above the joint line and the distal end of the stent 2 cm above the joint line.
- •ABI ≤ 0.9 at rest. Toe-Brachial Index (TBI) may be used if ABI is inadequate.
- •Lesion with a calcification percentage of at least 25% based on CTA evaluation (within 6 months of patient enrolment)
Exclusion Criteria
- •Acute critical limb ischemia
- •Untreated inflow disease of the ipsilateral pelvic arteries (more than 50 percent stenosis or occlusion).
- •Renal failure, creatinine clearance < 50 µmol /l
- •Severe allergy to iodine contrast
- •Patients with uncorrected bleeding disorders or patients who cannot receive anticoagulation or antiplatelet aggregation therapy
- •Lesions < 8 and > 20 cm in length
- •Calcification volume of less than 25%
Outcomes
Primary Outcomes
Stent expansion
Time Frame: At the completion of the intervention
Difference in minimal lumen diameter (MLD), minimal lumen area (MLA) and incomplete stent expansion as defined by C-arm CT between both groups
Secondary Outcomes
- Stent patency(1 year)
Investigators
Study Sites (4)
Loading locations...
Similar Trials
Completed
Phase 4
ORSIRO Stents Versus Xience PRIME Stents Assessed by Optical Coherence TomographyCoronary Heart DiseaseNCT01594736Deutsches Herzzentrum Muenchen30
Completed
Phase 3
Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)Coronary DiseaseNCT00165035Cordis Corporation1,701
Completed
Not Applicable
Evaluation of Long Coronary Artery Stents With Third-generation Dual-source Computed Tomography AngiographyChronic Total Occlusion of Coronary ArteryCoronary Artery DiseaseNCT06543641Lauri Mansikkaniemi45
Completed
Not Applicable
Optical Coherence Tomography to Improve Clinical Outcomes During Coronary AngioplastyAnginaNCT02065102Royal Infirmary of Edinburgh12
Completed
Not Applicable
A Comparison of Optical Coherence Tomography Guidance and Angiography-only Guidance for Percutaneous Coronary Intervention With Bioresorbable Vascular ScaffoldCoronary Artery DiseaseNCT02466282Yonsei University13